Search research articles
Contact Us
Filters
Showing results (681-690 of 737) with videos related to
Page
of 74
Sort By:
Blood
|
January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
Leukemia & Lymphoma
|
March 20, 2023
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia
Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 22, 2024
Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season
Jessie R Chung, Ashley M Price, Richard K Zimmerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 6, 2025
Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season
Jessie R Chung, Ashley M Price, Richard K Zimmerman, et al.
Vaccine
|
September 28, 2025
Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews
Paula M Campbell, Gabriella J Ess, Allison Lale, et al.
Antimicrobial Agents and Chemotherapy
|
September 13, 2021
Simultaneous Exposure to Intracellular and Extracellular Photosensitizers for the Treatment of Staphylococcus aureus Infections
Sydney L Drury, Anderson R Miller, Clare L Laut, et al.
The Lancet. Child & Adolescent Health
|
September 24, 2022
Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study
Ian Kracalik, Matthew E Oster, Karen R Broder, et al.
Influenza and Other Respiratory Viruses
|
June 26, 2024
Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023
Jessie R Chung, Philip Shirk, Manjusha Gaglani, et al.
The New England Journal of Medicine
|
May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
Vaccine
|
March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age
Theresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Page
of 74
Search research articles
Search
Showing results (681-690 of 737) with videos related to
Sort By:
Page
of 74
Blood
|
January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
Leukemia & Lymphoma
|
March 20, 2023
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia
Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 22, 2024
Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season
Jessie R Chung, Ashley M Price, Richard K Zimmerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 6, 2025
Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season
Jessie R Chung, Ashley M Price, Richard K Zimmerman, et al.
Vaccine
|
September 28, 2025
Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews
Paula M Campbell, Gabriella J Ess, Allison Lale, et al.
Antimicrobial Agents and Chemotherapy
|
September 13, 2021
Simultaneous Exposure to Intracellular and Extracellular Photosensitizers for the Treatment of Staphylococcus aureus Infections
Sydney L Drury, Anderson R Miller, Clare L Laut, et al.
The Lancet. Child & Adolescent Health
|
September 24, 2022
Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study
Ian Kracalik, Matthew E Oster, Karen R Broder, et al.
Influenza and Other Respiratory Viruses
|
June 26, 2024
Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023
Jessie R Chung, Philip Shirk, Manjusha Gaglani, et al.
The New England Journal of Medicine
|
May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
Vaccine
|
March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age
Theresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Page
of 74